Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
COMPASS Pathways announced the pricing of its upsized initial public offering (IPO) of 7,500,000 American Depositary Shares (ADSs) at $17.00 each, raising total gross proceeds of $127.5 million. The offering, which is managed by Cowen, Evercore ISI, and Berenberg, is expected to close around September 22, 2020, subject to customary conditions. The ADSs will begin trading on the Nasdaq Global Select Market under the ticker symbol CMPS. COMPASS focuses on innovative mental health treatments, particularly its psilocybin therapy for treatment-resistant depression.